H.B. Fuller outlines $650M-$675M FY2026 EBITDA range as it advances Advanced Medical Solutions acquisition (NYSE:FUL)

H.B. Fuller (FUL) raised its FY2026 EBITDA guidance to a $650M–$675M range, signaling management confidence in operational execution and synergy realization. The elevated outlook reflects both organic margin improvement and cash flow gains in the core adhesives and sealants business, which typically benefit from industrial activity normalization and pricing discipline.

The Advanced Medical Solutions acquisition represents a strategic pivot toward higher-margin, specialized solutions in medical device assembly. Synergy expectations embedded in the guidance suggest FUL anticipates meaningful cost absorption and cross-selling opportunities, reducing standalone AMS cost structure and broadening FUL's addressable market in healthcare manufacturing.

Leverage outlook improvement indicates management expects deleveraging from EBITDA growth and cash generation, reducing near-term refinancing risk and providing balance-sheet flexibility. This is material for credit-dependent industrial acquirers navigating a mixed-rate environment, as improving leverage ratios unlock future M&A optionality and shareholder return capacity.

Sector implication: The guidance raise and AMS synergy narrative support a constructive view on industrials-focused businesses with pricing power and acquisition discipline. However, the move remains company-specific rather than macro-signaling; broader industrial health depends on capex cycles and end-market demand, not single-name guidance raises.